# Long-Term Safety Extension Trial of Asenapine in Schizophrenia Participants Who Completed Protocol P05688 (P05689)

> **NCT01617200** · PHASE3 · COMPLETED · sponsor: **Forest Laboratories** · enrollment: 105 (actual)

## Conditions studied

- Schizophrenia

## Interventions

- **DRUG:** Asenapine
- **DRUG:** Placebo Asenapine
- **DRUG:** Olanzapine
- **DRUG:** Placebo Olanzapine

## Key facts

- **NCT ID:** NCT01617200
- **Lead sponsor:** Forest Laboratories
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-12
- **Primary completion:** 2015-03
- **Final completion:** 2015-03
- **Target enrollment:** 105 (ACTUAL)
- **Last updated:** 2015-05-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01617200

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01617200, "Long-Term Safety Extension Trial of Asenapine in Schizophrenia Participants Who Completed Protocol P05688 (P05689)". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01617200. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*